TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean numerical rating score for pain after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of subclinical arthropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Natural progression of subclinical arthropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Effectiveness of non-extraction orthodontic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Burden and Tumor Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of recurrent pleural effusions after chest tube removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores (VAS-Score)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in PTSD evaluation test scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Unscheduled bronchiolitis return visits
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Benefit of Analgesia Score (OBAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Competitive Employment Within Six Months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mononuclear cell responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recurrence of non-fatal ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Non-fatal Major Cardiac event
Endpoint domain: Mortality/survival
Primary endpoint: Anxiety level assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Volume assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-prandial glycemic excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pulmonary Stress Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence and grade of clinical laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Body Surface Area (BSA) involvement by GA lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of key complaint
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glycemic Control (Hemoglobin A1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Paneth cell numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma sRAGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps Rate of Torque Development (RTD) Maximum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Joint biomechanics during gait (nonlinear)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug efficacy assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of inhibition of SSc progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline joint pain of ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline joint function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in pneumonia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Restoration Survival
Endpoint domain: Mortality/survival
Primary endpoint: Intra ocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Plaque Index Scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety Scale for Children with Autism Spectrum Disorder (ASC-ASD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Observational Scale of Behavioral Distress (OSBD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: neuronal mechanisms of fear conditioning and extinction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the concentration-time curve (AUC) from time zero to infinity (AUC0-inf) of olinciguat in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of olinciguat in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal elimination half-life (t1/2) of olinciguat in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight for Length Z Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of nurse CDAI result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of nurse DAS-28 result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in low back pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol plasma concentration response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Growth of bacteria in drain fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Peak plasma concentration (Cmax) of salmeterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of fluticasone propionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of salmeterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Truncated area under the plasma concentration versus time curve (AUC) of salmeterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-operative leukocyte DNA methylation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure-free survival after 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Left Ventricular Outflow Tract (LVOT) gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Achieving LDL-C Target Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Arterial Stiffness Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of other treatments per patient
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time between two treatments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to maximum observed plasma concentration (tmax) of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (t1/2) of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Practice Improvement Module (PIM) quality impact
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gait spatio-temporal parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with PET/CT Scan Detection of Mantle Cell Lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Success of Stellate Ganglion Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inability to Walk 10 Feet or Across a Room Without Human Assistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in In Vehicle Data Recorder (IVDR) risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cue-elicited drug craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time of burst suppression percent during 1 minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional cerebral saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance of retainer wear
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in pulmonary function reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 24h NLR variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenotyping of innate lymphoid cells (ILC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful Stent/Coil Placement (Post Procedure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent Occlusion (Post Procedure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percent Stenosis (Post Procedure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mechanical power of the respiratory system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of composite endpoints of myocardial infarction, stroke, and any death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage Change of Area Under Curve for Urinary Prostaglandins Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurodevelopment at early childhood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptom reduction from reflux disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: composite outcome of nephrotoxicity or treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Viable bacterial levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Modified Bond-Lader Visual Analog Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: changes in flow-mediated dilation of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intima media thickness of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants at End of Study
Endpoint domain: Mortality/survival
Primary endpoint: Striatal D2 Receptor Binding Potential (D2BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The five-year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: BCVA in EDTRS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment Failure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Progressive Free Survival (rPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Knowledge about the preparation and administration of intravenous drugs in intensive care (post-test)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Positive and Negative Symptom Scale Excited Component (PANSS-EC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agitation-Calmness Scale (ACES)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Analgesic Effect (Pain on Average)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cerebral Blood Flow velocity (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain rating (0-100 on a visual analogue scale, VAS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Accurate diagnosis of Silent Sinus Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant infectious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects gaining 15 or more letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Laboratory Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacterial genomic signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serotype specific geometric mean antibody concentrations (GMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CIED Implantation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: NAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of intercurrent illness
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adrenal crisis
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overactive bladder symptoms score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Assays on blood and serum samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in decisional conflict score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: freedom from clinically-driven target lesion revascularization (CD-TLR) at 12 months post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of participants who deceased, had major amputation, or target vessel revascularization (CD-TVR)
Endpoint domain: Adverse events/effects
Primary endpoint: Trainees' feelings about using simulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in respiration and airway physiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Antiviral treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of Use Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Formation of intrauterine adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Evaluation of rectus diastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of IDOX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgery or catheter-based procedure related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Anti HBs Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Migration of the OptEase™ IVC filter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Symptomatic thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Measurement of pathological beta-amyloid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Freedom from AF/Atrial Flutter/Atrial Tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective Response Rate in the Central Nervous System (CNS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall response rate to rituximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Eczema area and severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scoring atopic dermatitis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve of the Analyte From Time 0 to the Last Quantifiable Data Point (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of single dose IGIMRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postpartum hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of serotype-specific B cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urinary Phthalates concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Social participation and activity
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Success Rate of standard medical management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turning Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnetic stimulation pressure measure (Pstim)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Edinburgh Postnatal Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Brief Index of Sexual Functioning for Women scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Infusion-Associated Reactions (IAR)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in total number of hours worked
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total Daily Symptom Score (TDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Side effects of study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Disease activity score DAS28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Successful Performances among patients in whom BCI is attempted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Pneumothorax requiring Tube Thoracostomy
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean titer and frequency of 4-fold or greater increases in serum hemagglutination inhibition (HAI) antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects achieving a serum neutralizing antibody titer ratio of 1:40 against the influenza A/H5N1 virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects achieving a serum hemagglutination (HAI) antibody titer of 1:40 against the influenza A/H5N1 virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average Cost Per Participant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Relative skeletal muscle index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pathologic Complete Response to Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sialorrhea Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved Clinical Benefit as Determined by RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Response (DOR) for Small Cell Lung Cancer (SCLC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who experience severe toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Use PAM Device
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Minute Ventilation at the 55 mm Hg End Tidal Carbon Dioxide Point (VE55)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Technetium Tc99m Sestamibi activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients who sign consent form
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Peak Plasma Concentration of Nitroglycerine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of neuropsychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Candesartan concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved clinical benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyography results of the pectoral muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: global outcome according to treatment choice
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Population prevalence of Gaucher disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Adverse events associated with oral sulforaphane
Endpoint domain: Adverse events/effects